Trial Profile
Prospective Randomized Clinical Trial for no Inferiority With Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery (TEM) Versus Total Mesorectal Excision in T2-T3s N0, M0 Rectal Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Oct 2022
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms The TAUTEM-study
- 08 Oct 2022 Results published in the Annals of Oncology
- 07 Jun 2022 Results reporting efficacy and safety data presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 15 Nov 2021 Status changed from recruiting to completed.